- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00968864
T-cell Depleted Alternative Donor Transplantation
A Phase II Study Using the CliniMACS® Device for CD34+ Cell Selection and T Cell Depletion for Graft-versus-Host Disease Prophylaxis in Alternative Donor Stem Cell Transplant Recipients
The primary purpose is to determine the ability of CD34+ selection and T cell depletion using the CliniMACS® device to prevent severe acute graft-versus-host disease (GVHD) in patients receiving a stem cell transplant from an alternative (unrelated and mismatched related) donor. The secondary objectives include evaluation of engraftment, immune recovery, and post-transplant infections.
Patients requiring stem cell transplants for either malignant (cancerous) or non-malignant disease will be included in the study. The recipients will be grouped into one of two groups based on whether the donor is mismatched related (Cohort A) or unrelated (Cohort B). The patient will receive a conditioning regimen including chemotherapy drugs and/or total body irradiation based on the disease for which the transplant is performed.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Levine Children's Hospital, Carolinas Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age < 30 years
- Patient must have a malignant or non-malignant disease that can benefit from alternative stem cell transplantation. Examples include acute and chronic leukemias, myelodysplastic syndrome, lymphoma, severe acquired and congenital cytopenias, white and red blood cell abnormalities, and immunodeficiencies.
- Patients with acute lymphoblastic leukemia must be in morphological remission (< 5% blasts) at the time of transplant. Patients with acute non-lymphocytic leukemia will preferably be in morphologic remission but may be enrolled when aplastic after chemotherapy or with < 20% blasts. Patients with lymphoma must be in complete or close to complete remission (if residual adenopathy, PET scan must be negative or only have slight uptake, eg. SUV < 2).
- Patients must lack a healthy HLA-identical related donor of at least one year of age.
Patient must have a mismatched related or an unrelated donor who is:
- Able to receive G-CSF and undergo apheresis either through placement of catheters in antecubital veins or a temporary central venous catheter,
- Healthy,
- Willing,
- For recipients of an unrelated donor transplant, recipient eligibility will be restricted as follows if in the judgment of the recipients' transplant physician, the recipient cannot receive a transplant with combined positive and negative fractions as described in Section 6.1.3.2 or an unmanipulated PBSC product.
- Meets eligibility criteria for donors.
- If only one mismatched related relative is available, an acceptable unrelated donor must be identified as a backup.
- Patient or authorized guardian must sign informed consent for this study.
Exclusion Criteria:
- Patient with an anticipated life expectancy of < 1 month
- Active infectious hepatitis or CMV infection
- HIV or HTLV-I/II infection
- Serious infection (bacterial, fungal, viral) within the last 4 weeks
- Cardiac ejection fraction < 45%; can be lower if patient is not in clinical cardiac failure and a reduced intensity conditioning regimen is used.
- Creatinine clearance <60 ml/min/1.72 m2; can be lower if a reduced intensity conditioning regimen is used.
- Pulmonary diffusion capacity (adjusted for Hgb), FEV1, or FVC <60% of predicted or O2 sat < 94% if unable to perform PFTs; can be lower if a reduced intensity conditioning regimen is used.
- Serum ALT > 3 x upper limit of normal (can be up to 5 x upper limit of normal if a reduced intensity conditioning regimen is used) or bilirubin > 2. The bilirubin criteria for sickle cell disease patients is direct bilirubin >2x upper limit of normal.
- Performance score (Lansky/Karnofsky) < 50
- Any condition that compromises compliance with the procedures of this protocol, as judged by the principal investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CliniMACS® (T cell depletion)
Recipients will receive T cell-depleted PBSC from eligible donors after receiving conditioning therapy using CliniMACS® device.
|
Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF).
The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells.
Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Severe Graft vs. Host Disease (GVHD).
Time Frame: Within 30 days after stem cell transplant
|
Severe GVHD defined as grade III/IV GVHD.
|
Within 30 days after stem cell transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: 2 years
|
2 years
|
|
Number of Participants With Engraftment and Time to Engraftment
Time Frame: Within 28 days after stem cell transplant
|
Engraftment was measured as time to absolute neutrophil count >500
|
Within 28 days after stem cell transplant
|
Number of Participants With Post-transplant Infections
Time Frame: 1 year
|
1 year
|
|
Number of Participants With EBV-related Post Transplant Lymphoproliferative Disorder (PTLD)
Time Frame: 5 years
|
5 years
|
|
Number of Participants With Post-transplant Leukemia Relapse
Time Frame: 5 years
|
5 years
|
|
Number of Participants With Transplant-related Mortality
Time Frame: 2 year
|
Transplant-related mortality includes death due to regimen-related toxicity or GVHD (all causes other than disease relapse).
Those who died due to disease relapse are not included in the analyzed population for that time point.
|
2 year
|
Number of Participants With Transplant-related Toxicities
Time Frame: 1 year
|
1 year
|
|
Device Performance: Dose of CD34+ Cells and CD3+ Cells Given
Time Frame: Length of the trial (5 years)
|
For mismatched related donors, the target cell dose after processing is >/= 20 x 10^6 CD34+ cells/kg patient body weight, but >/= 8 x 10^6 is acceptable. For unrelated donors the target cell dose after processing is >/= 10 x 10^6 CD34+ cells/kg patient body weight, but >/= 4 x 10^6 is acceptable. The target T cell dose is </= 3 x 10^4 CD3+ cells/ kg. |
Length of the trial (5 years)
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Bone Marrow Diseases
- Hematologic Diseases
- Genetic Diseases, Inborn
- Musculoskeletal Diseases
- Myeloproliferative Disorders
- Bone Diseases
- Leukemia, Lymphoid
- Bone Diseases, Developmental
- Osteochondrodysplasias
- Osteosclerosis
- Myelodysplastic Syndromes
- Leukemia
- Leukemia, Myeloid
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Immunologic Deficiency Syndromes
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Hemoglobinopathies
- Bone Marrow Failure Disorders
- Pancytopenia
- Osteopetrosis
Other Study ID Numbers
- LCH BMT 09-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
Jacqueline Garcia, MDEli Lilly and CompanyCompletedCombination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid LeukemiaRelapsed Adult Acute Myeloid Leukemia | Refractory Adult Acute Myeloid LeukemiaUnited States
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
Clinical Trials on CliniMACS® (T cell depletion)
-
Julie-An M. TalanoMiltenyi Biotec, Inc.Active, not recruitingHematologic MalignanciesUnited States
-
Rajni AgarwalCompletedMalignant Diseases | Non-malignant DiseasesUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials...CompletedLeukemia, Myelocytic, AcuteUnited States
-
Neena Kapoor, M.D.Terminated
-
University of ChicagoRecruitingSickle Cell DiseaseUnited States
-
Children's Hospital of PhiladelphiaCompletedImmunodeficienciesUnited States
-
Children's Hospital of PhiladelphiaAvailableLeukemia | Immunodeficiencies | Bone Marrow Failure SyndromeUnited States
-
University of Kansas Medical CenterIn8bio Inc.RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia | Chronic Myeloid LeukemiaUnited States
-
Neena Kapoor, M.D.Not yet recruitingAcute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Hematologic Malignancy | Graft Vs Host Disease | Graft-versus-host-disease | Non-hematologic Malignancy
-
Nationwide Children's HospitalActive, not recruitingHematologic Malignancy | MyelodysplasiaUnited States